I'm here to answer your questions about our people-focused, technology-enabled biopharma services.
Outsourcing global clinical
& medical engagement for accelerated drug approval
& acceptance
No image found.
Precision medicine (PM), or personalized medicine, brings new hope to patients with cancer, with treatments tailored to individual genetic profiles. And it’s evolving quickly.
By the numbers: According to the Journal of Oncology Navigation & Survivorship, in the past 5 years, 60% of approved cancer treatments required or recommended biomarker testing before use. Plus, many of the drugs in clinical trials today are tied to the use of an FDA-approved biomarker test to determine access to therapy.
Why it matters: Many patients miss out on personalized oncology treatments due to barriers like operational inefficiencies, cost, limited understanding of biomarker strategies, misuse of testing results, and access issues. In fact, according to JCO Precision Oncology, 64% of eligible patients who have advanced non-small cell lung cancer are not receiving precision oncology therapies, highlighting a major gap in personalized medicine in oncology.
This care disparity is both a clinical and business problem, affecting pharmaceutical companies’ reach and market share in precision oncology.
While manufacturers expect several high-leverage PM approvals in 2024 and 2025, the crowded oncology market presents several obstacles:
Bottom line: Succeeding in PM launches requires a thoughtful + multipronged approach, including patient support, creative communications strategies + a prepared field force.
Amplity is a full-service go-to partner delivering specialized + flexible medical and sales teams. While fluent in therapeutic areas across the medical spectrum, our core strengths are oncology, rare disease + specialty therapies.